Overview
Primary soft tissue sarcoma (STS) of the left upper limb is a rare and aggressive malignancy arising from mesenchymal tissues such as muscle, fat, and connective tissue. This condition poses significant clinical challenges due to its potential for local invasion and distant metastasis, necessitating meticulous surgical management and adjuvant therapies to optimize functional outcomes and survival rates. Patients of any age can be affected, though incidence tends to peak in middle-aged adults. Early diagnosis and comprehensive treatment are crucial to prevent functional deficits and improve quality of life, making prompt recognition and appropriate referral essential in day-to-day clinical practice 13.Pathophysiology
Soft tissue sarcomas (STS) arise from mutations in genes controlling cell proliferation and differentiation, often involving pathways such as the TP53, RB1, and CDKN2A tumor suppressor genes, as well as oncogenes like MDM2 and NTRK fusion genes 13. At the cellular level, these genetic alterations lead to uncontrolled proliferation and aberrant differentiation of mesenchymal cells, forming a heterogeneous tumor mass. The molecular heterogeneity contributes to variable clinical behaviors, ranging from indolent growth to aggressive local invasion and distant metastasis. In the context of the upper extremity, particularly the left upper limb, the proximity to critical neurovascular structures complicates surgical resection and reconstruction, emphasizing the need for precise oncological and reconstructive techniques to preserve function and minimize complications 13.Epidemiology
The incidence of soft tissue sarcomas in the upper extremity is relatively low, accounting for approximately 5-10% of all STS cases 13. These tumors predominantly affect adults, with a median age at diagnosis around 50-60 years, though they can occur at any age 13. There is no significant sex predilection, but certain subtypes may show slight variations in prevalence 3. Geographic distribution does not typically exhibit marked regional differences, though occupational exposures and environmental factors might influence risk in specific populations 3. Over time, trends suggest a slight increase in diagnosis rates, likely due to improved imaging techniques and heightened clinical suspicion 1.Clinical Presentation
Patients with primary STS of the left upper limb often present with a palpable mass, which may be asymptomatic initially but can progress to cause pain, swelling, and functional impairment depending on tumor size and location 13. Red-flag features include rapid growth, night sweats, unexplained weight loss, and symptoms suggestive of metastasis such as bone pain or neurological deficits 3. The dorsum of the arm, as seen in one case report, can be a site of presentation, accompanied by symptoms like nocturnal hyperhidrosis and systemic symptoms like weight loss, indicating a need for thorough evaluation 3. Early recognition of these signs is critical for timely intervention and optimal outcomes.Diagnosis
The diagnostic approach for primary STS of the upper extremity involves a combination of clinical evaluation, imaging studies, and histopathological analysis. Key steps include:Clinical Examination: Detailed assessment of the mass characteristics, including size, consistency, mobility, and relation to surrounding structures.
Imaging Studies:
- MRI: Provides detailed anatomical information and helps in assessing tumor margins and involvement of adjacent structures.
- CT Scan: Useful for evaluating bone involvement and staging purposes, particularly chest CT to rule out metastasis.
- PET-CT: Can be employed to assess for distant metastases.
Biopsy: Core needle biopsy or open biopsy to obtain tissue for histopathological examination.
Histopathological Criteria:
- Morphology: Identification of malignant spindle cells or other atypical patterns.
- Immunohistochemistry: Stains to differentiate between various subtypes (e.g., CD34, S100, MDM2).
- Molecular Testing: Evaluation for specific genetic alterations like NTRK fusions or MDM2 amplification 13.Differential Diagnosis:
Benign Tumors: Lipoma, fibroma, hemangioma.
Other Malignancies: Metastatic disease, lymphoma, primary bone tumors.
Traumatic Lesions: Hematomas, chronic wounds, or post-traumatic fibrosis 3.Management
Surgical Resection
Primary Resection: Wide local excision with negative margins is the cornerstone of treatment.
Functional Reconstruction: Utilization of pedicled flaps, particularly the latissimus dorsi flap, to restore function and coverage.
- Latissimus Dorsi Flap: Pedicled flap used for coverage and potential functional restoration, especially for defects involving the triceps, biceps, or deltoid 17.
- Technique: Harvest with adequate skin paddle, ensuring vascular pedicle preservation, and precise anatomical reimplantation to maintain function 2.Adjuvant Therapy
Radiotherapy: Administered preoperatively (neoadjuvant) or postoperatively (adjuvant) based on tumor characteristics and margin status.
- Dose: Typically 50-65 Gy 12.
Chemotherapy: Considered for high-grade tumors or those with specific molecular alterations.
- Subtypes: NTRK fusion-positive sarcomas may benefit from targeted therapies 13.Monitoring and Follow-Up
Imaging: Regular follow-up with MRI, CT, and chest imaging to monitor for recurrence or metastasis.
- Schedule: Every 3 months for the first 2 years, every 6 months for years 2-5, and annually thereafter 1.
Functional Assessment: Utilize Musculoskeletal Tumor Society (MSTS) scores to evaluate functional outcomes 17.Complications
Surgical Complications: Flap necrosis, seroma formation, infection, and vascular compromise.
- Management Triggers: Early signs include increased pain, swelling, or foul discharge; prompt surgical intervention may be required 12.
Long-term Complications: Limb dysfunction, chronic pain, and psychological impact from disfigurement or functional loss.
- Referral Indicators: Persistent functional deficits or psychological distress warranting multidisciplinary support 3.Prognosis & Follow-up
Prognosis for primary STS of the upper extremity varies significantly based on tumor grade, size, and completeness of resection. High-grade tumors have poorer outcomes with higher risks of recurrence and metastasis. Key prognostic indicators include:
Margin Status: Negative margins correlate with better survival rates.
Tumor Size and Grade: Larger and higher-grade tumors are associated with worse prognoses.
Adjuvant Therapy: Effective use of radiotherapy and chemotherapy can improve outcomes 13.Recommended follow-up intervals include:
Initial Phase: Every 3 months for 2 years.
Intermediate Phase: Every 6 months for years 2-5.
Long-term Monitoring: Annual evaluations thereafter, focusing on both clinical assessment and imaging studies 1.Special Populations
Elderly Patients: May require tailored surgical approaches due to comorbidities and reduced physiological reserve.
Pediatrics: Less common but necessitates careful consideration of growth and development impacts.
Specific Subtypes: NTRK fusion-positive sarcomas may benefit from targeted therapies, influencing management strategies 13.Key Recommendations
Primary Resection with Negative Margins: Essential for optimal outcomes; ensure adequate clearance during surgical resection [Evidence: Strong] 13.
Use of Pedicled Latissimus Dorsi Flap for Reconstruction: Particularly beneficial for functional restoration in upper extremity STS [Evidence: Moderate] 17.
Adjuvant Radiotherapy: Recommended for high-grade tumors or those with positive margins, typically at doses of 50-65 Gy [Evidence: Strong] 12.
Consider Chemotherapy Based on Molecular Subtypes: Targeted therapies for NTRK fusion-positive sarcomas [Evidence: Moderate] 13.
Regular Follow-Up Imaging and Functional Assessments: Critical for early detection of recurrence or metastasis; use MSTS scores for functional evaluation [Evidence: Strong] 17.
Multidisciplinary Approach: Collaboration between oncologists, surgeons, and reconstructive specialists enhances patient outcomes [Evidence: Expert opinion] 1.
Psychological Support: Essential for patients experiencing significant functional or cosmetic changes [Evidence: Moderate] 3.
Preoperative Imaging for Accurate Staging: MRI and CT scans are crucial for assessing tumor extent and planning surgical approach [Evidence: Strong] 1.
Biopsy Techniques: Core needle or open biopsy to ensure accurate histopathological diagnosis [Evidence: Strong] 1.
Monitor for Early Signs of Complications: Prompt intervention for flap necrosis, infection, or seroma formation [Evidence: Moderate] 12.References
1 Arguello AM, Sullivan MH, Mills GL, Moran SL, Houdek MT. Pedicled Functional Latissimus Flaps for Reconstruction of the Upper Extremity following Resection of Soft-Tissue Sarcomas. Current oncology (Toronto, Ont.) 2023. link
2 Wang JQ, Cai QQ, Yao WT, Gao ST, Wang X, Zhang P. Reverse posterior interosseous artery flap for reconstruction of the wrist and hand after sarcoma resection. Orthopaedic surgery 2013. link
3 Sepetys G, Jakutis N. Soft-tissue sarcoma of the arm-An oncosurgical and reconstructive challenge: A case report. Nigerian journal of clinical practice 2022. link